Zymeworks Advances Biotherapeutic Pipeline in 2024
Company Announcements

Zymeworks Advances Biotherapeutic Pipeline in 2024

Zymeworks ( (ZYME) ) has issued an announcement.

Zymeworks Inc. has made significant strides in 2024, marking pivotal advancements in their biotherapeutic pipeline. Key highlights include dosing the first patient in a Phase 1 trial of ZW171 for MSLN-expressing cancers and presenting promising preclinical data on ADC candidates ZW220 and ZW251. Their partner, Jazz Pharmaceuticals, has submitted a New Drug Application for zanidatamab, a HER2-targeting antibody, potentially leading to a U.S. approval for biliary tract cancer. With a robust cash position of $374.9 million, Zymeworks is strategically expanding its focus on innovative therapies, aiming for long-term growth and transformative patient care.

Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyZymeworks reports Q3 EPS (39c), consensus (40c)
TipRanks Canadian Auto-Generated NewsdeskZymeworks to Spotlight Innovations at Investor Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App